⚖️ Drug Manufacturers - Specialty & Generic
Industry peer comparison — 31 companies ranked by market cap. Click any column header to sort; click a symbol for its full fundamentals page.
AI-assisted data: figures are extracted from public quarterly filings with AI assistance,
under human editorial oversight, and may still contain errors — verify against official filings. Educational
information only, not financial advice.
| # | Company | CMP (₹) | MCap (Cr) | P/E | Sales TTM (Cr) | NP TTM (Cr) | OPM % | NPM % | Sales YoY % | NP YoY % | Qtr Rev Δ% | Qtr NP Δ% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1,840.00 | 441,478 | 36.5 | 59,911 | 12,104 | 29.8% | 20.2% | 11.2% | 5.1% | 10.5% | 27.0% | |
| 2 | 9,235.00 | 245,160 | 83.8 | 11,230 | 2,925 | 35.3% | 26.0% | 12.8% | 16.7% | 27.8% | 65.5% | |
| 3 | 4,931.00 | 187,559 | 87.1 | 15,723 | 2,156 | 33.0% | 13.7% | 21.4% | 11.9% | 54.8% | 3.3% | |
| 4 | 1,162.20 | 115,930 | 23.2 | 27,148 | 5,070 | 31.2% | 18.7% | 16.8% | 12.0% | 16.2% | 14.5% | |
| 5 | 1,366.00 | 110,353 | 32.7 | 28,324 | 3,356 | 18.7% | 11.8% | 2.2% | -26.7% | 2.3% | -39.2% | |
| 6 | 1,969.00 | 106,387 | 97.2 | 7,270 | 1,090 | 28.0% | 15.0% | 22.7% | 147.9% | 29.1% | 123.9% | |
| 7 | 1,165.50 | 97,085 | 29.3 | 28,704 | 3,273 | 15.3% | 11.4% | -10.4% | -25.8% | -5.6% | -69.2% | |
| 8 | 1,679.80 | 96,652 | 26.2 | 34,935 | 3,711 | 20.3% | 10.6% | 6.1% | 0.6% | 16.3% | 25.2% | |
| 9 | 2,095.00 | 95,797 | 17.9 | 27,958 | 5,356 | 31.5% | 19.2% | 23.1% | 62.0% | 31.9% | 87.8% | |
| 10 | 2,280.00 | 94,174 | 46.1 | 14,738 | 2,067 | 26.0% | 14.0% | 16.3% | -3.7% | 12.9% | 29.1% | |
| 11 | 2,419.20 | 68,276 | 38.0 | 17,737 | 1,797 | 27.0% | 10.1% | -61.2% | -67.4% | 23.1% | 927.9% | |
| 12 | 5,243.50 | 62,694 | 29.1 | 15,081 | 2,187 | 20.1% | 14.5% | 13.5% | 7.6% | 10.9% | -21.6% | |
| 13 | 25,860.00 | 54,951 | 34.0 | 7,005 | 1,615 | 28.1% | 23.1% | 8.1% | 9.7% | 4.4% | 17.2% | |
| 14 | 1,964.20 | 49,833 | 38.0 | 10,125 | 1,379 | 22.0% | 13.6% | 7.9% | 55.0% | 20.8% | 82.2% | |
| 15 | 2,935.90 | 48,433 | 47.1 | 6,431 | 1,028 | 25.3% | 16.0% | -64.7% | -48.4% | 22.3% | 96.7% | |
| 16 | 3,398.90 | 42,472 | 37.4 | 5,777 | 1,135 | 25.4% | 19.7% | 17.3% | 14.8% | 24.8% | 30.9% | |
| 17 | 2,416.10 | 38,793 | 53.4 | 4,148 | 709 | 26.7% | 17.1% | 5.9% | 7.5% | -4.8% | -30.7% | |
| 18 | 1,975.10 | 37,470 | 37.0 | 9,684 | 1,019 | 20.4% | 10.5% | 16.6% | 33.1% | 22.8% | 36.0% | |
| 19 | 2,021.50 | 32,848 | 92.5 | 3,133 | 353 | 19.9% | 11.3% | -2.3% | 342.1% | 25.9% | 199.1% | |
| 20 | 23,455.00 | 30,093 | 82.7 | 2,023 | 365 | 28.4% | 18.0% | 37.0% | 40.2% | 136.3% | 666.0% | |
| 21 | 211.50 | 28,024 | 113.5 | 9,206 | 247 | 11.0% | 2.7% | -3.1% | -37.9% | 17.4% | -161.3% | |
| 22 | 885.60 | 21,945 | 32.8 | 5,633 | 663 | 22.7% | 11.8% | 19.7% | 18.8% | 22.0% | 59.3% | |
| 23 | 2,752.60 | 20,923 | 31.4 | 2,287 | 678 | 34.8% | 29.7% | 12.9% | 20.2% | 19.6% | 18.8% | |
| 24 | 1,358.00 | 18,820 | 29.0 | 3,230 | 666 | 35.2% | 20.6% | 8.2% | 72.6% | 13.0% | 14.6% | |
| 25 | 6,755.00 | 16,888 | 99.6 | 2,432 | 170 | 9.4% | 7.0% | 32.7% | 62.1% | 29.7% | -32.1% | |
| 26 | 439.55 | 16,817 | n/m | 2,141 | 58 | 14.8% | 2.7% | 141.4% | -18.1% | -23.1% | -197.4% | |
| 27 | 1,322.70 | 16,239 | 26.9 | 2,590 | 603 | 32.3% | 23.3% | 6.9% | 16.5% | 6.4% | 31.2% | |
| 28 | 1,022.15 | 16,190 | 46.2 | 8,607 | 351 | 14.1% | 4.1% | -8.9% | -64.3% | 1385.3% | 3217.6% | |
| 29 | 792.00 | 15,568 | 22.5 | 7,784 | 692 | 15.0% | 8.9% | 10.1% | 15.4% | 25.7% | 12.7% | |
| 30 | 816.50 | 14,891 | 13.3 | 3,484 | 1,083 | 30.2% | 31.1% | -7.9% | -27.5% | -44.7% | -55.5% | |
| 31 | 258.85 | 11,392 | 105.1 | 2,253 | 136 | 18.3% | 6.0% | 88.2% | 387.6% | 128.9% | 560.0% |
TTM = trailing twelve months. Banks/NBFCs show total income in the sales column.
Live prices refresh about twice a day. Educational information only — not financial advice.
